Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 272 clinical trials
featured
HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma

of agents such as VEGF, mTOR inhibitors and immunotherapy (high-dose (HD) IL-2 or immune-checkpoint inhibitors). Long-term survival can be achieved with high-doses IL-2 or immune-checkpoint inhibitors

renal cell cancer
clear cell carcinoma
carcinoma
metastatic cancer
primary cancer
  • 144 views
  • 22 Dec, 2020
  • 1 location
Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors

-cell component, who progressed after prior Checkpoint Inhibitors (CPI) therapy with ipilimumab and nivolumab in combination or CPI combined with Vascular Endothelial Growth Factor (VEGF)-targeted

  • 2 views
  • 19 Sep, 2021
  • 78 locations
Phase III Study Assessing the Efficacy Safety and Immunogenicity of SOK583A1 Versus Eylea in Patients With Neovascular Age-related Macular Degeneration

clinical question of interest is: Does SOK583A1 have similar efficacy as Eylea EU in terms of mean change in BCVA score in participants with nAMD who are anti-VEGF naive, without important protocol

  • 1 views
  • 19 Sep, 2021
  • 43 locations
The Sahlgrenska Anti-VEGF Study

The study investigates whether patients treated for neovascular (wet) age-related macular degeneration (AMD), with intravitreal injection with bevacizumab (Avastin) after two years need more injections with retained therapy response compared to patients being treated with intravitreal injection with aflibercept (Eylea). The study also aims to evaluate if there is a …

  • 0 views
  • 04 Feb, 2021
  • 1 location
Bevacizumab In Hereditary Hemorrhagic Telangiectasia

Telangiectasia (HHT) is a disorder that causes abnormal blood vessel formation. In HHT, there is a mutation in the TGF- pathway, which results in an increase of vascular endothelial growth factor (VEGF) levels

  • 0 views
  • 10 Jul, 2021
  • 1 location
The Study of Drug 601 in Patients With Wet Age-related Macular Degeneration (wAMD)

Multicenter study to evaluate the safety and tolerability in patients with wet Age-related macular degeneration (wAMD) treated with intravitreal recombinant humanized anti-VEGF monoclonal

  • 0 views
  • 25 Jan, 2021
601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)

To evaluate the safety and efficacy of intravitreal recombinant humanized anti-VEGF monoclonal antibody in patients with visual impairment due to pmCNV

  • 0 views
  • 23 Jun, 2021
  • 1 location
Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome

blindness by suppressing the neovascular phase of ROP the visual outcomes after treatment are often poor. Vascular endothelial growth factor(VEGF) has an important role in the pathogenesis of ROP

vegf
bevacizumab
vascular endothelial growth factor
antiangiogenic therapy
blindness
  • 4 views
  • 07 Nov, 2020
  • 1 location
Impact of Endostar Combined With Chemotherapy on the Angiogenesis of Advanced Non-small Cell Lung Cancer (NSCLC)

combined with docetaxel and cisplatin) and group two (docetaxel and cisplatin). - The serum concentrations of Endostatin,VEGF and bFGF are determined. - Blood circulating endothelial

docetaxel
stage iv non-small cell lung cancer
lung cancer
tumor angiogenesis
cancer
  • 11 views
  • 07 Nov, 2020
  • 1 location
Intravitreal Conbercept Injection in Patients With Myopic Choroidal Neovascularization

-vascular endothelial growth factor (VEGF) drugs would significantly suppress the activity of the CNV and finally improve the visual acuity. However, more than half of the patients would need one or more

  • 0 views
  • 02 May, 2021
  • 1 location